Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The role of GSK3 on macrophage re-programming by high-dose methotrexate

ABSTRACT: The role of GSK3 on macrophage re-programming by high-dose methotrexate

PROVIDER: PRJNA771078 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16324040.fastq.gz	Fastqsanger.gz
	SRR16324041.fastq.gz	Fastqsanger.gz
	SRR16324042.fastq.gz	Fastqsanger.gz
	SRR16324043.fastq.gz	Fastqsanger.gz
	SRR16324044.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

The role of GSK3 on macrophage re-programming by high-dose methotrexate

Project description:Macrophage phenotypic and functional heterogeneity derives from tissue-specific transcriptional signatures shaped by the local microenvironment. M-CSF drives the generation of human monocyte-derived macrophages with a potent anti-inflammatory activity upon stimulation. One-carbon metabolism (OCM) is a complex network of biosynthetic pathways that includes de novo biosynthesis of purines and thymidylate, amino acid metabolism, and methylation reactions. Methotrexate (MTX) is an anti-folate drug used for Acute Lymphoblastic Leukemia treatment. We explored the molecular impact of blocking GSK3 a/b on the transcriptional effect of high-doses of MTX in M-CSF-primed human monocyte derived macrophages.

2023-10-01 | GSE185872 | GEO

Methotrexate Clearance

Project description:Methotrexate Clearance

| PRJNA76037 | ENA

Metabolic re-programming by MALAT1 depletion in prostate cancer

Project description:Metabolic re-programming by MALAT1 depletion in prostate cancer

| PRJNA615392 | ENA

Inhibition of Hepatocellular Carcinoma Progression by Forced Metabolic Re-Programming

Project description:Inhibition of Hepatocellular Carcinoma Progression by Forced Metabolic Re-Programming

| PRJNA478592 | ENA

Caco2 response to methotrexate, lactoferrin, and methotrexate-lactoferrin co-exposure

Project description:bulk sequencing outputs of Caco2 cells after exposure to permeability modifying and permeability rescuing agents. To identify the molecular drivers for methotrexate-induced barrier dysfunction, we conducted RNA sequencing on Caco2 spheroids treated with methotrexate and lactoferrin. Given our observation that barrier function was compromised as early as 4-6 hours after exposure to methotrexate, we isolated RNA from spheroids 4-hour post-treatment to capture the transcriptional events responsible for initiating the processes.

2020-01-10 | GSE140066 | GEO

Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients

Project description:<p>We estimated the plasma clearance of methotrexate from 1279 acute lymphoblastic leukemia (ALL) patients treated on the Children Oncology Group 9904 and 9905 trials (<a href="http://clinicaltrials.gov/show/NCT00005585">http://clinicaltrials.gov/show/NCT00005585</a> and <a href="http://clinicaltrials.gov/show/NCT00005596)">http://clinicaltrials.gov/show/NCT00005596</a>). Patients received either a 24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose). Methotrexate clearance was lower in older children (p=7 x 10-7), females (p=2.7 x 10-4), and patients who received a delayed intensification phase (p=0.0022). In a genome-wide analysis, methotrexate clearance was associated with polymorphisms in the SLCO1B1 gene (p=2.1 x 10-11), which encodes for an organic anion transporter. This replicates findings using different schedules of high-dose methotrexate in ALL patients treated on St. Jude protocols. A combined meta-analysis yields a p-value of 5.7 x 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056 (Trevino et al, PMID 19901119 and Ramsey et al, PMID 23233662). This data set includes the dependent variable of methotrexate clearance and all of the SNP data available from arrays.</p>

| phs000637.v1.p1 | EGA